In vivo effects of a novel calcium antagonist (R56865) against induced epoxyscillirosidin and tulp poisoning in sheep.
Two anaesthetized sheep were intoxicated with epoxyscillirosidin, the main cardio-active bufadienolide, extracted from Homeria pallida (Natal yellow tulp). The epoxyscillirosidin was injected intravenously as a bolus of 50 micrograms/kg, followed 30 min later by a continuous infusion in a normal saline drip (0.9% NaCl) at 25 micrograms/kg/h. In addition, another two conscious sheep were poisoned by intraruminal dosing of 1,25 g/kg of dried H. pallida plant material. Electrocardiograms, heart and respiratory rates and venous-acid-base levels were recorded prior to and at approximately 30-60 min intervals during the course of the experiment. Additional recordings were made when animals showed signs of intoxication. R56865 (Janssen Pharmaceutica, Pty Ltd), a novel Ca++ antagonist, was administered at the first distinct signs of cardiac disturbances in the sheep given epoxyscillirosidin and after development of tachycardia and dyspnoea in those that received plant material. Activated charcoal was drenched at 3 g/kg to both sheep that received H. pallida about 1 h after the initial administration of R56865. All H. pallida sheep and one of the epoxyscillirosidin sheep survived. The signs of intoxication with H. pallida, namely groaning and tachypnoea, abated within minutes of treatment with R56865, but returned c. 30 min later in both animals. The treatment apparently had little effect on heart rate and EKG changes. One of the epoxyscillirosidin sheep was treated while exhibiting paroxysmal ventricular tachycardia. Although a transient improvement in conduction disturbance was recorded, the animal died soon afterwards. The results of this study indicate that the in vivo response of R56865 against induced bufadienolide cardiac disturbance in sheep is not as evident as that observed with R56865 against similar cardiac disturbance in vitro. The potential use of R56865 together with activated charcoal is discussed.
Swan
G E
GE
Department of Pharmacology and Toxicology, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.
Schultz
R A
RA
Kellerman
T S
TS
Mülders
M S
MS
Maartens
B P
BP
Van der Walt
J J
JJ
D000818:Animals; D052160:Benzothiazoles; D002018:Bufanolides; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002770:Cholenes / Q000302:isolation & purification; D066298:In Vitro Techniques; D010880:Piperidines / Q000627:therapeutic use*; D010936:Plant Extracts / Q000302:isolation & purification; D010939:Plant Poisoning / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*; D012756:Sheep; D012757:Sheep Diseases / Q000188:drug therapy*; D013844:Thiazoles / Q000627:therapeutic use*; D014118:Toxins, Biological / Q000302:isolation & purification
D052160:Benzothiazoles; D002018:Bufanolides; D002121:Calcium Channel Blockers; D002770:Cholenes; D010880:Piperidines; D010936:Plant Extracts; D013844:Thiazoles; D014118:Toxins, Biological; C087925:bufadienolide; C054551:R 56865